Sulfaquinoxaline sodium is used in veterinary-only oral and injectable dosage forms as the freely water-soluble salt of sulfaquinoxaline. The free acid is practically insoluble in neutral aqueous media; therefore the sodium salt is specified for drinkable solutions, injectable solutions, and solid dosage forms where dissolution is required, whereas the base is reserved for suspensions and certain oral preparations where a low-solubility depot or gut-localised effect is intended. The downstream selection begins with salt form and water content. Because sulfaquinoxaline sodium is hygroscopic, storage at relative humidity above 60 % produces surface hydration, powder bridging, and loss of flow in feed hoppers. Transfer into a closed mixing train should be completed within 2 hours when the room dew point exceeds 16 °C. Material release includes identity by infrared spectrophotometry or liquid chromatography, water content by Ph. Eur. 2.2.32, related substances by Ph. Eur. 2.2.29, and sub-visible particulate matter for injectable grades by Ph. Eur. 2.9.19. A laser diffraction D₉₀ below 250 µm is commonly used for solid oral forms to support content uniformity; the final value is fixed in the marketing authorisation and is not a general pharmacopoeial requirement. The API must be protected from light and from oxidising agents. Stainless steel 316L or glass-lined vessels are preferred because prolonged contact with iron or copper can promote discolouration in alkaline solutions. Published data for the specific particle size of a given commercial sulfaquinoxaline sodium lot is limited; each batch is therefore qualified by physical characterisation before first use in a formulation.

The veterinarian selects the route according to species and flock size. Water-dispersible powders and granules are suited to mass medication of poultry and rabbits because treatment can be applied through drinking water without handling individual animals. Tablets and capsules are more common for calves and young ruminants, where individual dosing is possible and water intake may be depressed during clinical coccidiosis. Injectables are reserved for animals that cannot drink, or where rapid systemic exposure is required. This route division creates different formulation demands: oral powders prioritise reconstitution and drinker-line compatibility, solid dosage forms prioritise content uniformity and dissolution, and injectables prioritise sterility, endotoxin control, and particulate matter limits.

For tablet compression, sulfaquinoxaline sodium is rarely direct-compressed because the high dose fraction and cohesive nature of the API produce unacceptable weight variation on direct-compression machines. For a 500 mg sulfaquinoxaline tablet, the active fraction may exceed 60 % w/w. Dry granulation via roller compaction is used for moisture-sensitive formulations; a common starting point is roll pressure of 40–60 bar, a roll gap of 1.5–2.0 mm, and milling through an oscillating sieve with 1.0 mm apertures. The granules are blended with microcrystalline cellulose, croscarmellose sodium, and colloidal silicon dioxide; magnesium stearate is added at 0.5–1.0 % w/w. Higher lubricant levels lower tablet tensile strength and delay dissolution. Compression on an instrumented rotary press with 8 mm B tooling is run at speeds that maintain sufficient dwell time for plastic deformation of the granule; excessively short dwell time can cause capping at the upper tablet face. Weight variation is controlled by Ph. Eur. 2.9.5, uniformity of dosage units by Ph. Eur. 2.9.40, and dissolution by USP <711> in a neutral or mildly alkaline medium to avoid in-situ precipitation of the free acid. If the tablet contains the poorly soluble base, dissolution is more sensitive to particle size and granule porosity; a D₉₀ below 50 µm for the base is often necessary to achieve the label claim. Tablet cores may be film-coated with HPMC-based systems when light protection or taste masking is required; the coating must not interfere with dissolution, and the tablet must still meet the finished-product test.

What Shifts Sulfaquinoxaline Sodium from a Freely Soluble Salt to an Undissolved Free Acid in Oral Liquids?

Reconstituted oral solutions and drinking-water treatments are prepared by dissolving sulfaquinoxaline sodium in potable water. The salt produces a clear alkaline solution; however, the sulfonamide anion behaves as the conjugate base of a weak acid. When the pH of the water falls below the pK_a of the sulfonamide, protonation converts the anion to un-ionised sulfaquinoxaline free acid, which precipitates as a fine sediment. Field failures are observed when acidic well water is used, when the solution is combined with acidified vitamin or electrolyte concentrates, or when the product is diluted into a metal trough containing residual disinfectant. The precipitate reduces the effective dose, accumulates in drinker lines, and can block nipple drinkers.

Formulators limit this risk by including an alkaline buffer such as trisodium citrate or sodium carbonate in the dry powder. The amount of buffer is selected after solubility screening in the intended farm water source; hard water with a calcium carbonate equivalent above 300 mg/L may require a higher buffer level than soft water. Because solubility decreases as temperature falls, reconstitution is tested at 10 °C as well as at 25 °C. The dry mixture is tested for loss on drying by Ph. Eur. 2.2.32, reconstitution time and residue by an in-house method, and uniformity of mass for sachets by Ph. Eur. 2.9.5. Single-dose sachets are additionally controlled for uniformity of dosage units by Ph. Eur. 2.9.40. The oral liquid should be used within the time stated on the label because photodegradation of sulfonamides in dilute solution can generate coloured degradation products that adsorb onto plastic lines.

For capsule manufacture on a dosator-type machine, sulfaquinoxaline sodium requires tighter powder-flow control than dry blending for sachets. The cohesive crystals tend to arch over the dosator nozzle when tapped density is below 0.45 g/cm³; therefore the formulation is often precompacted to increase bulk density or granulated with a polyvinylpyrrolidone binder. For low-dose capsules containing a potentiator, segregation risk is reduced by ordered mixing: the lower-dose active is first blended with a fine lactose carrier having a D₅₀ below 100 µm, then the sulfaquinoxaline sodium and extragranular disintegrant are added in a stepwise manner. Gelatin capsule shells may require desiccant protection because the sodium salt can transfer moisture and soften the shell at high relative humidity. Hard gelatin capsules are filled on a tamping pin or auger machine; fill weight is monitored by Ph. Eur. 2.9.5. Dissolution testing for capsules uses USP <711> apparatus II in a neutral or slightly alkaline buffer. Acidic media such as 0.1 M hydrochloric acid are avoided because the free acid precipitates in situ and creates a false dissolution failure. If a capsule formulation contains the base rather than the sodium salt, dissolution is more sensitive to the particle size of the active; micronisation of the base to a D₉₀ below 10 µm may be needed to achieve acceptable release. Published data for this specific base micronisation and capsule formulation is limited.

The processing controls for each dosage form are summarised below. The reference methods are current pharmacopoeial methods that are commonly cited in registration dossiers for veterinary sulfaquinoxaline sodium products; limits are dosage-form and species dependent and are not given as universal values.

High-shear wet granulation of oral granules and water-dispersible powders

Wet granulation of sulfaquinoxaline sodium is performed in a high-shear mixer-granulator equipped with an impeller and side chopper. Because the sodium salt is freely water-soluble, a purely aqueous granulation fluid can dissolve the API at the liquid bridges, leading to hard, dense granules after drying and slower reconstitution. Hydroalcoholic binder solutions with an ethanol content of 40–60 % are therefore used to limit solubilisation. The binder is typically polyvinylpyrrolidone K30 or pregelatinised starch; the exact level is fixed by granule porosity. A common starting operation uses an impeller speed of 150–300 rpm and a chopper speed of 1500–3000 rpm, but these values must be scaled from the mixer diameter. The wet mass is screened through a 1.25 mm mesh and dried in a fluid-bed dryer with an inlet air temperature of 50–60 °C. Drying is stopped when the loss on drying by Ph. Eur. 2.2.32 reaches the registered range, often between 1.0 % and 2.5 %. Over-drying below 0.5 % increases granule friability and dust generation; under-drying above 3.0 % causes caking in sachets and reduces flow into tablet dies.

After drying, the granules are screened to remove the oversized fraction. The final blend contains extragranular croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate at 0.5–1.0 % w/w. Exceeding the upper magnesium stearate limit can delay dissolution because the hydrophobic film retards water penetration. Granule size distribution is monitored by sieve analysis; a D₅₀ between 100 µm and 300 µm is typical for water-dispersible powders. The finished granules are packed into foil-lined sachets because aluminium foil provides moisture, light, and oxygen protection. Reconstitution of the sachet content in drinking water is evaluated at the lowest labelled water temperature; residues through a 0.25 mm sieve are controlled by the in-house method. Uniformity of mass is tested by Ph. Eur. 2.9.5. If the sachet is a single-dose oral granule, uniformity of dosage units is tested by Ph. Eur. 2.9.40.

Injectable aqueous solutions demand oxygen exclusion, alkaline pH, and light-protected packaging

Injectable sulfaquinoxaline sodium solutions are prepared with water for injections at concentrations such as 200 mg/mL expressed as sulfaquinoxaline base. The sodium salt is added to cooled water for injections below 25 °C to reduce local heating during hydration. The pH is adjusted with dilute sodium hydroxide to a registered alkaline range; if the pH is allowed to fall, the free acid precipitates. The solution is purged with nitrogen before and after filling to reduce oxidative discoloration. Antioxidant systems and buffering agents require compatibility screening because alkaline sulfonamide solutions can degrade some phenolic preservatives and can attack glass surfaces over time. Filtration is performed through a 0.45 µm prefilter followed by a 0.22 µm hydrophilic PVDF or PES membrane. Cellulose ester membranes are less suitable for strongly alkaline solutions. The solution is filled into amber Type I glass vials or multilayer plastic bottles; headspace oxygen should be below 2 % where terminal sterilisation is not used. Terminal moist-heat sterilisation at 121 °C for 15 minutes can be used only after thermal challenge data demonstrate no precipitation, no increase in related substances beyond the registered limit, and no pH drift. When terminal sterilisation is not possible, the solution is sterilised by filtration and filled aseptically. Sterility is tested by Ph. Eur. 2.6.1, bacterial endotoxins by Ph. Eur. 2.6.14, sub-visible particulate matter by Ph. Eur. 2.9.19, and uniformity of content in filled containers by Ph. Eur. 2.9.40 where single-dose containers are used. The solution must not be frozen; freezing can concentrate the solute and cause crystallisation of the API. At the point of injection, the operator should use the needle size stated in the veterinary labelling; the aqueous solution has low viscosity and can be drawn through a 21 G needle under normal farm conditions.

Injectable suspension dosage forms use sulfaquinoxaline base rather than the sodium salt because the practically insoluble free acid provides a slow-release depot after intramuscular or subcutaneous administration. The base is micronised or wet-milled to a D₉₀ below 10 µm to prevent needle clogging and minimise tissue irritation. The aqueous vehicle contains a wetting agent such as polysorbate 80 or lecithin, a flocculating agent such as sodium citrate, and a preservative where a multi-dose container is registered. The suspension is prepared in a high-shear mixer followed by a piston-gap homogeniser or ball mill; particle size is monitored by laser diffraction and sub-visible particulate matter by Ph. Eur. 2.9.19. Sedimentation volume and resuspendability after storage at 25 °C and 5 °C are controlled by in-house methods. The finished suspension is filled aseptically into glass vials or syringes; terminal sterilisation is generally not feasible because the dispersed particles can aggregate under thermal load. Sterility is tested by Ph. Eur. 2.6.1 and bacterial endotoxins by Ph. Eur. 2.6.14. Syringeability through a 21 G needle is checked after 30 seconds of vigorous shaking; resuspendability failure is a common reason for batch rejection when the particle size distribution shifts during long-term storage. The use of a base suspension is not interchangeable with an aqueous solution of the sodium salt because the pharmacokinetic release profile differs and the withdrawal period may not be the same.

When Sulfaquinoxaline Sodium Is Co-formulated with a Diaminopyrimidine Potentiator

Sulfonamide monotherapy is not used where potentiation is required. Sulfaquinoxaline sodium is co-formulated with a dihydrofolate reductase inhibitor such as diaveridine in certain oral water-dispersible powders for poultry. The two actives block sequential steps in folate synthesis; the fixed proportion is defined by the registered product, and published data for this specific configuration is limited outside the dossier. Because the two powders have different particle densities, a simple physical mixing operation can produce segregation. Ordered mixing is therefore used: the lower-dose potentiator is blended with a fine lactose or mannitol carrier before the sulfaquinoxaline sodium is added. Mixing time is established by content uniformity studies using Ph. Eur. 2.9.40; excessive blending can generate electrostatic charge and reverse the effect. The mixture is packed in foil-lined sachets and stored below 25 °C. Accelerated stability at 40 °C and 75 % relative humidity may produce yellowing and an increase in related substances; therefore water vapour permeation through the packaging must be controlled. Dissolution or reconstitution of the combination product is carried out in the intended drinking water pH range. The farm user must be instructed to avoid acidified co-administered products and to flush the drinker lines after the treatment period; the withdrawal period is species-specific and must appear on the label.